The mood at BIO 2026 in San Diego felt noticeably brighter than recent industry gatherings, with artificial intelligence and federal policy dominating hallway conversations among global delegations. STAT reporters who attended the annual biotech conference shared their on-the-ground takeaways on the latest episode of the STATus Report, hosted by senior multimedia producer Alex Hogan.

A global gathering with a different energy

If the J.P. Morgan Healthcare Conference is often called the "Super Bowl of biotech," BIO plays more like the World Cup, drawing delegations from dozens of countries. The big question heading in was straightforward: what would the vibes be like?

After some distinctly downbeat moods at other major events over the past year, the reporting team was struck by how different this one felt. The shift in tone, even more than any single announcement, became the story worth telling from the show floor. A more optimistic backdrop also tracked with a busy dealmaking year, with pharma and biotech M&A reportedly totaling around $123 billion in 2026.

Who was reporting and what they tracked

The coverage pulled together perspectives from across the STAT newsroom. The on-site team included:

  • Meghana Keshavan - biotech correspondent focused on the science and dealmaking side.
  • Brittany Trang - health tech reporter tracking how AI is moving into drug development and care.
  • Daniel Payne - Washington correspondent watching how federal policy ripples through the industry.

Together they gathered vibe checks from industry leaders, capturing how much a single year can change the outlook for companies navigating funding, regulation and new technology.

AI, China and policy set the agenda

Two themes ran underneath the brighter mood. AI keeps moving from buzzword to working tool inside drug discovery and clinical operations, a shift our AI coverage tracks closely. And federal policy decisions continue to shape funding and approval timelines that companies cannot control on their own, from Eli Lilly's obesity-drug access fight to FDA enforcement touching wearable maker Whoop.

China's role also loomed large. A gene-editing startup, Serapha Bio, drew attention with a roughly $230 million round and a Chinese licensing deal, underscoring how cross-border science and capital are reshaping the pipeline. For executives, those threads are not abstract: they feed directly into how confidently companies plan their next year.

Why the takeaways matter

Conference sentiment is a leading indicator for an industry that lives on confidence, capital and timing. A more optimistic BIO suggests executives feel steadier about the road ahead, even as questions about AI's real role and shifting federal policy hang over the sector.

BIO is one of the industry's largest annual gatherings, the kind of event where partnering meetings, policy panels and hallway conversations can shape deals for months. That scale is exactly why the overall mood carries weight: thousands of executives reading the same room tend to act on what they sense there. The broader message from BIO 2026 was simple: the energy is back, and the next year will test whether it holds. Follow the wider sector in our latest news.

Frequently asked questions

What were the main themes at BIO 2026?

AI moving into drug discovery and clinical work, federal policy effects on funding and approvals, and China's growing role in biotech all dominated, against an improved overall mood and a roughly $123 billion M&A year.

Who covered BIO 2026 for STAT?

Alex Hogan hosted the STATus Report recap, with reporting from biotech correspondent Meghana Keshavan, health tech reporter Brittany Trang and Washington correspondent Daniel Payne.